BRAF and melanoma: Nelfinavir efficiently suppressed PAX3 and MITF expression in a panel of BRAF mutant melanoma cells (Figures 3A and B) and reduced the GI50 for the MEK inhibitor selumetinib in drug-tolerant A375 melanoma cells (A375-T) by ∼60-fold, comparable with the GI50 in sensitive cells (Figure 3C).